Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lung Cancer Group Cologne
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent
≥ 18 years of age
Untreated non-small-cell lung cancer stage IIIB/IV
Life expectancy \> 3 months
Performance status ECOG 0-2
You may not be if
Concurrent systemic immune therapy, chemotherapy or therapy with any anticancer drug not indicated in the study protocol
Any investigational agent(s) within 4 weeks prior to study entry
Previous administration of any EGFR-targeted therapy (antibodies, small molecules and others)
Any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information
Clareo Health | Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)
